4//SEC Filing
BOSTON SCIENTIFIC CORP 4
Accession 0001225208-17-005433
$BSXCIK 0000885725operating
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:17 PM ET
Size
15.3 KB
Accession
0001225208-17-005433
Insider Transaction Report
Form 4
Dawkins Keith D
Sr. VP, Chief Medical Officer
Transactions
- Award
Common Stock
2017-02-28+22,934→ 105,384 total - Tax Payment
Common Stock
2017-02-28$24.55/sh−11,955$293,495→ 98,165 total - Exercise/Conversion
Common Stock
2017-02-28+4,736→ 110,120 total - Exercise/Conversion
Deferred Stock Units
2017-02-28−4,736→ 4,736 total→ Common Stock (4,736 underlying) - Sale
Common Stock
2017-02-28$24.64/sh−30,000$739,134→ 68,165 total - Award
Performance Share Units
2017-02-28+9,923→ 9,923 totalFrom: 2018-12-31Exp: 2018-12-31→ Common Stock (9,923 underlying)
Footnotes (7)
- [F1]On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person was based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2016 and was subject to the completion of the concurrent three-year individual service period. On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F2]Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F3]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.625 to $24.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
- [F5]Reflects multiple DSU awards with independent vesting schedules.
- [F6]Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F7]On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will be prorated and released following retirement.
Documents
Issuer
BOSTON SCIENTIFIC CORP
CIK 0000885725
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000885725
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 7:17 PM ET
- Size
- 15.3 KB